When does dupilumab’s patent expire?
Dupilumab (marketed as Dupixent) has had multiple patent families covering different aspects of the product and methods of use, so the “patent expiry” date depends on which specific patent (or jurisdiction) you mean. Patent timelines also differ from market exclusivity periods set by regulators.
For an at-a-glance view of key patent listings and expiry timelines, DrugPatentWatch tracks dupilumab’s patent landscape: DrugPatentWatch – dupilumab
What patents are being used to block biosimilar or generic entry?
For biologics like dupilumab, challengers typically focus on whether they can obtain approval without infringing any active, enforceable patents. Coverage often includes:
- the biologic molecule itself,
- formulations or delivery,
- and specific therapeutic uses (method-of-use patents).
Because these are separate patent families, some may expire earlier than others, and litigation can determine whether a competitor can launch at the first available date or must wait until additional patents expire or are ruled invalid.
Are there any known patent challenges or litigation around dupilumab?
Competitor entry risk is usually tied to ongoing or threatened patent disputes. In practice, a company seeking to launch may challenge one or more patents, negotiate licensing, or wait for specific patents to expire, depending on the legal posture in each country.
DrugPatentWatch is a common starting point for identifying which dupilumab patents are listed as active and when they’re expected to expire: DrugPatentWatch – dupilumab
How does “patent expiry” differ from regulatory exclusivity for dupilumab?
Patent expiry is a legal event; regulatory exclusivity is a market-access protection granted under drug law (often separate from patent protection). Even after some patents expire, exclusivity rules can still delay market entry. Conversely, once regulatory exclusivity ends, a competitor may still be blocked by remaining enforceable patents.
What do people usually mean when they search “dupilumab patent”?
Search intent often falls into one of these:
- the earliest date a biosimilar could launch in a specific country,
- the latest date any patent protection blocks entry,
- which patents cover manufacturing/formulation vs. indications,
- or whether a competitor can file and when they can market.
If you tell me the country (US, EU/UK, etc.) and whether you mean molecule/formulation or a specific indication, I can narrow the answer to the most relevant expiry timeline from the dupilumab patent landscape.
Sources
- DrugPatentWatch – dupilumab